Digital Health in Pediatric Oncology and Hematooncology: A Quasi-Systematic Review of Telehealth, mHealth and Precision Medicine

儿科肿瘤和血液肿瘤学中的数字健康:远程医疗、移动医疗和精准医学的准系统性综述

阅读:1

Abstract

Pediatric oncological and hematological diseases remain a significant challenge due to their complexity, the need for personalized treatment, and long-term follow-up. Recent advances in medical technologies, particularly in information technology (IT), telemedicine, mobile health (mHealth), and precision medicine, have opened new possibilities for improving care and supporting clinical decision-making in pediatric patients. This quasi-systematic review examines the current landscape of emerging technologies applied in pediatric oncology and hematology. A structured literature search was conducted in MEDLINE (PubMed), Web of Science, Scopus, and Google Scholar between March and April 2024, covering studies published from January 2018 to February 2024. A total of 157 met the predefined inclusion criteria. A critical analysis was performed regarding the clinical utility, implementation readiness, and limitations of these technologies, with particular attention to developmental variability and pediatric-specific safety requirements. Telehealth and mHealth tools were identified as effective solutions to improve accessibility and continuity of care by enabling remote consultations, real-time monitoring, and enhanced patient and family engagement. Precision medicine approaches demonstrated improved progression-free survival in selected high-risk pediatric populations, while AI-based tools supported diagnostic and prognostic decision-making. Despite these advances, the overall evidence remains heterogeneous, with limited high-quality randomized trials and scarce long-term cost-effectiveness evaluations. Ethical, infrastructural, and economic barriers continue to affect widespread implementation. A multidimensional and system-oriented approach is required to effectively integrate innovative technologies into real-world pediatric oncology and hematooncology settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。